Company Filing History:
Years Active: 2000
Title: The Innovative Contributions of Susan Light
Introduction
Susan Light is a notable inventor based in Menlo Park, California. She has made significant contributions to the field of organ transplantation through her innovative methods aimed at preventing acute rejection following solid organ transplants. Her work has the potential to improve the outcomes for transplant patients significantly.
Latest Patents
Susan Light holds a patent for a method of preventing acute rejection following solid organ transplantation. This invention provides methods that entail administering a monoclonal antibody, which binds to the p55 subunit of the human interleukin-2 (IL-2) receptor of human T lymphocytes. The monoclonal antibody is preferably a chimeric or humanized antibody that blocks the binding of IL-2 to the IL-2 receptor. In some methods, a single dose of about 1 mg/kg of antibody is administered every other week, commencing immediately prior to transplantation and continuing until eight weeks after transplantation. This innovative approach has the potential to enhance the success rates of organ transplants.
Career Highlights
Susan Light is associated with Protein Design Labs, Inc., where she has been able to apply her expertise in the development of therapeutic solutions for transplant patients. Her work at the company has been instrumental in advancing the understanding and treatment of organ rejection.
Collaborations
One of her notable collaborators is Cary L. Queen, who has worked alongside her in various projects related to organ transplantation and immunology. Their combined efforts have contributed to the development of groundbreaking methods in the field.
Conclusion
Susan Light's innovative work in preventing acute rejection following organ transplantation showcases her dedication to improving patient outcomes. Her contributions to the field are invaluable and highlight the importance of continued research and innovation in medical science.